Karoly Nikolich is Strategic Innovation Advisor with Grifols. During the 1980s, he led Genentech’s entry into neuroscience and led and participated in the development of numerous protein therapeutics. 
He was Vice President of Research at Lynx Therapeutics, co-founder of AGY Therapeutics, Amnestix, Neurofluidics, Chase Pharmaceuticals, Circuit Therapeutics, Engrail, Addition Therapeutics, and Alkahest. He has also served as a venture partner with Pivotal BioVentures and has been on the boards and scientific advisory boards of a number of neurotherapeutics and biotech companies.

He currently serves as Chair on the Board of Directors at Alkahest, a Grifols company, and is a member of the Board of Directors of Engrail Therapeutics. He has been an Adjunct Professor in the Department of Psychiatry at Stanford University Medical School.
Dr. Nikolich is a graduate of Eotvos University in Budapest and worked as a postdoctoral fellow at Tulane University and UCSF before joining Genentech.